B. Riley Wealth Advisors’s Sonoma Pharmaceuticals SNOA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-83
Closed -$22K 731
2018
Q3
$22K Sell
83
-24
-22% -$8.72K ﹤0.01% 712
2018
Q2
$48K Sell
107
-18
-14% -$11.7K 0.01% 664
2018
Q1
$83K Buy
125
+43
+52% +$35.3K 0.01% 633
2017
Q4
$81K Buy
+82
New +$70.2K 0.01% 617
2017
Q1
Sell
-58
Closed -$53K 559
2016
Q4
$53K Buy
+58
New +$48.1K 0.01% 516
2016
Q3
Sell
-103
Closed -$75K 653
2016
Q2
$75K Sell
103
-36
-26% -$31K 0.02% 580
2016
Q1
$89K Buy
139
+7
+5% +$6.5K 0.02% 516
2015
Q4
$137K Buy
132
+11
+9% +$11.7K 0.03% 508
2015
Q3
$142K Buy
121
+17
+16% +$20.2K 0.03% 493
2015
Q2
$135K Buy
104
+14
+16% +$13.1K 0.03% 482
2015
Q1
$68K Sell
90
-22
-20% -$18.7K 0.02% 518
2014
Q4
$667 Buy
112
+47
+72% +$73.2K 0.01% 835
2014
Q3
$138K Buy
65
+17
+35% +$39.5K 0.04% 549
2014
Q2
$134K Sell
48
-12
-20% -$35.5K 0.03% 604
2014
Q1
$203K Buy
60
+14
+30% +$47.6K 0.06% 383
2013
Q4
$144K Sell
46
-20
-30% -$53.2K 0.05% 453
2013
Q3
$162K Buy
66
+18
+38% +$43.8K 0.06% 401
2013
Q2
$112K Buy
+48
New +$172K 0.04% 513

Other funds holding SNOA

B. Riley Wealth Advisors's SNOA Position: Q4 2018 in Review

B. Riley Wealth Advisors sold out of Sonoma Pharmaceuticals (SNOA) in Q4 2018, closing a stake of 83 shares — an estimated $22K sold.

B. Riley Wealth Advisors first reported a position in SNOA in Q2 2013 and held it in 18 quarters. The position peaked at $203K in Q1 2014. 18 funds tracked by Wall St. Rank hold SNOA as of Q4 2018.

  • B. Riley Wealth Advisors reported no remaining Sonoma Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 83 Sonoma Pharmaceuticals shares in Q4 2018, an estimated $22K.
  • B. Riley Wealth Advisors first reported a position in Sonoma Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • B. Riley Wealth Advisors's Sonoma Pharmaceuticals position peaked at $203K in Q1 2014.
  • 18 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q4 2018.

Based on B. Riley Wealth Advisors's 13F filing for Q4 2018, filed 8 Feb 2019.